Highest-materiality recent filing
Eli Lilly completes $6.75/share buyout of AtaiBeckley (ATAI); CVRs worth up to $2.50
Merger closed Sept 11: each ATAI share converted to $6.75 cash plus one CVR (up to $2.50) on milestones.
AtaiBeckley stockholders approve Eli Lilly merger; closing expected Sept 11, 2026
Merger proposal approved: 237,762,253 shares for, 5,033,755 against, 555,549 abstentions.
ATAI's merger with Eli Lilly clears US HSR and UK CMA; Australian waiting period expires Sept 10
US HSR waiting period for ATAI-Eli Lilly merger expired at 11:59 p.m. ET on Aug 28, 2026.
AtaiBeckley to be acquired by Eli Lilly for $6.75/share plus CVRs up to $2.50/share
Merger consideration: $6.75 per share cash plus one CVR per share with potential milestone payments up to $2.50 per share.
AtaiBeckley shareholders elect three directors, ratify Deloitte as auditor at annual meeting
Sabrina Martucci Johnson, Amir Kalali, and Andrea Heslin Smiley elected as Class I directors for three-year terms.
AtaiBeckley to present at June 2026 conferences; will highlight BPL-003 Phase 3 initiation
Jefferies Global Healthcare Conference fireside chat on June 3, 12:15 PM ET.
AtaiBeckley Q1 net loss $29.8M; BPL-003 Phase 3 initiation on track for Q2 2026
Cash and equivalents $209.9M as of March 31, 2026; runway into 2029.
AtaiBeckley enters into new ATM equity offering agreement with Jefferies
ATM allows AtaiBeckley to sell common stock via Jefferies as sales agent, replacing prior 2022 agreement.
AtaiBeckley reports Q4/FY2025: net loss $660M; BPL-003 Phase 3 on track for Q2 2026
Cash $220.7M as of Dec 31, 2025; runway to early 2029 topline readouts.
AtaiBeckley reports pro forma combined net loss of $704M for 2025 after Beckley Psytech acquisition
Pro forma combined net loss attributable to common stockholders $704.3M, or $3.11 per diluted share, for FY 2025.
EMP-01 met primary safety objective; no serious AEs, no suicidal behavior.
AtaiBeckley appoints Michael Faerm CFO effective March 9, 2026; Johnson becomes CAO
Michael Faerm appointed CFO of AtaiBeckley, effective March 9, 2026; Anne Johnson becomes Chief Accounting Officer.
AtaiBeckley provides 2026 milestones; BPL-003 Phase 3 start Q2'26, VLS-01 data H2'26
BPL-003 (mebufotenin) Phase 2b TRD trial met primary and all key endpoints; Phase 3 guidance Q1'26, trial start Q2'26 pending FDA End-of-Phase 2 meeting.
AtaiBeckley completes redomiciliation to Delaware; stock continues trading as ATAI on Nasdaq
Redomiciliation from Netherlands to Delaware completed on Dec 30, 2025; approved by ~99% of votes cast.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
at the Effective Time, Christopher Anderson and Jonathan R. Haug, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
at the Effective Time, Christopher Anderson and Jonathan R. Haug, the directors of Merger Sub immediately prior to the Effective Time, became directors of the Company.
at the Effective Time, the officers of Merger Sub immediately prior to the Effective Time, Jonathan R. Haug as President, Steffanie Lim-Ho as Treasurer, Christopher Anderson as Secretary, Jonathan Groff as Assistant Secretary, Jamie Burnett as Assistant Secretary and Katie Lodato as Assistant Treasurer, became the officers of the Company.
Max materiality 1.00 · Median 0.65 · Most common event other_material